Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Anti-oestrogen therapies are crucial for hormone-sensitive breast cancers.
• Acquired resistance to anti-oestrogens like ICI 182780 limits treatment efficacy.
• Understanding resistance mechanisms is vital for improving breast cancer treatment strategies.

Purpose of the Study:

• To investigate the molecular mechanisms underlying acquired resistance to the anti-oestrogen ICI 182780 in breast cancer cells.
• To compare oestrogen receptor (ER) expression, function, and regulation between sensitive and resistant cell lines.
• To identify differentially expressed genes contributing to anti-oestrogen resistance.

Main Methods:

• Comparative analysis of MCF-7 (sensitive) and MCF-7/182R-6 (ICI 182780-resistant) human breast cancer cell lines.
• Assessment of oestrogen receptor (ER) protein and mRNA levels, ER binding affinity, and downstream target gene expression (progesterone receptor).
• In vitro growth assays under varying conditions (oestradiol, ICI 182780) and gene expression profiling.

Main Results:

• MCF-7/182R-6 cells exhibit reduced ER protein levels but retain ER binding function.
• Loss of oestrogen-induced progesterone receptor expression in resistant cells.
• ICI 182780 treatment leads to rapid ER protein degradation, suggesting decreased protein stability.
• Resistant cells display an oestradiol-independent growth phenotype, growing in the absence or presence of ICI 182780.
• Limited differences in gene expression were observed between sensitive and resistant cell lines.

Conclusions:

• Anti-oestrogen resistance in breast cancer cells can arise from altered ER protein stability.
• The development of resistance is associated with an oestradiol-independent phenotype.
• A relatively small number of molecular changes likely contribute to anti-oestrogen resistance.